Roehrborn C G
Department of Urology, UT Southwestern Medical Center, Dallas, TX, USA.
Int J Impot Res. 2008 Dec;20 Suppl 3:S19-26. doi: 10.1038/ijir.2008.53.
Several analyses have demonstrated a clinically useful relationship between serum prostate specific antigen (PSA) and prostate volume in men with benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). Both prostate volume and serum PSA predict certain aspects of the natural history of LUTS and BPH, and men with higher PSA and larger glands in general have a higher rate of progression measured by various parameters. Serum PSA also predicts the response to certain types of medical therapy in men with LUTS and BPH and is thus useful in the evaluation and management of these patients. Lastly, serum PSA does not loose its usefulness as a cancer marker for prostate cancer even if certain medications reduce serum PSA values predictably by 50%.
多项分析表明，在患有良性前列腺增生（BPH）和下尿路症状（LUTS）的男性中，血清前列腺特异性抗原（PSA）与前列腺体积之间存在临床上有用的关系。前列腺体积和血清PSA都能预测LUTS和BPH自然病程的某些方面，一般来说，PSA较高且腺体较大的男性，通过各种参数测量的进展率更高。血清PSA还能预测LUTS和BPH男性对某些类型药物治疗的反应，因此对这些患者的评估和管理很有用。最后，即使某些药物可预期地使血清PSA值降低50%，血清PSA作为前列腺癌的癌症标志物的作用也不会丧失。
